Angiomatosis - 25 Studies Found
| Terminated |
: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease :
: 2009-11-16 : Drug: Avastin Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months |
| Completed |
: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 :
|
| Active, not recruiting |
: Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease :
: 2000-06-06 |
| Active, not recruiting |
: Von Hippel-Lindau Disease Genetic Epidemiology Study :
: 1999-11-03 |
| Completed |
: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy :
|
| Active, not recruiting |
: Pazopanib in Von Hippel-Lindau (VHL) Syndrome : Von Hippel-Lindau Syndrome : 2011-09-15 : Drug: Pazopanib 800 mg by mouth once daily for up to six, four week cycles. |
| Terminated |
: TKI 258 in Von Hippel-Lindau Syndrome (VHL) : Von Hippel-Lindau Syndrome : 2010-12-22 : Drug: Dovitinib 500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cy |
| Terminated |
: Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome : Von Hippel-Lindau Syndrome : 2008-05-06 : Drug: Sunitinib Malate Participants were expected to receive 9 months of sunitinib malate therapy admini |
| Completed |
: Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome : Von Hippel-Lindau Syndrome : 2004-08-12 : Drug: Ranibizumab |
| Recruiting |
: PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma :
|